Drugs Made In America Acquisition Corp. (DMAA) Financial Statements
Industry: Blank Checks
In fiscal 2025, Drugs Made In America Acquisition reported revenue of $0. Net income was $5.9M, or $0.19 per diluted share. Operating activities generated -$539,187 of cash. At fiscal year end, Drugs Made In America Acquisition held $239.9M in total assets against $7.3M in total liabilities.
Open the full interactive Drugs Made In America Acquisition financials → Quarterly statements, key ratios, valuation history and price charts.
Drugs Made In America Acquisition Key Stats
| Share Price | $10.86 |
|---|---|
| Market Cap | $218.2M |
| P/E Ratio | 57.2 |
| 52-Week Range | $10.29 – $10.89 |
| Shares Outstanding | 20.1 million (basic, 2026 Q2) |
Drugs Made In America Acquisition Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Goods Sold | $0 | — |
| Gross Profit | $0 | — |
| Operating Income | — | -$2.8M |
| Pre-Tax Income | $0 | $5.9M |
| Net Income | $0 | $5.9M |
| Diluted EPS | — | $0.19 |
Drugs Made In America Acquisition Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | $2.2M | $212,958 | $2.0M | $1.7M |
| Diluted EPS | $0.07 | $0.01 | $0.06 | $0.06 |
Drugs Made In America Acquisition Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Current Assets | $4,991 | $12,191 |
| Total Assets | $550,824 | $239.9M |
| Current Liabilities | — | $376,172 |
| Total Long-Term Debt | — | $1.1M |
| Total Liabilities | $795,669 | $7.3M |
| Shareholders' Equity | -$244,845 | -$7.3M |
Drugs Made In America Acquisition Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$172,265 | -$539,187 |
| Cash From Investing | — | -$231.2M |
| Cash From Financing | $173,616 | $231.7M |
Figures from Drugs Made In America Acquisition's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Drugs Made In America Acquisition financials page for every line item.
Drugs Made In America Acquisition Company Profile
| Ticker | DMAA |
|---|---|
| Exchange | Nasdaq |
| Industry | Blank Checks |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002028614 |
Frequently Asked Questions
What was Drugs Made In America Acquisition's revenue in fiscal 2025?
Drugs Made In America Acquisition (DMAA) reported revenue of $0 for fiscal 2025.
What was Drugs Made In America Acquisition's net income in fiscal 2025?
Drugs Made In America Acquisition reported net income of $5.9M for fiscal 2025.
What was Drugs Made In America Acquisition's earnings per share (EPS) in fiscal 2025?
Drugs Made In America Acquisition's diluted EPS was $0.19 for fiscal 2025 (adjusted for any later stock splits).
What was Drugs Made In America Acquisition's revenue last quarter?
In its most recent reported quarter (2026 Q2), Drugs Made In America Acquisition reported revenue of $0.
How much debt does Drugs Made In America Acquisition have?
Drugs Made In America Acquisition reported $1.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Drugs Made In America Acquisition are outstanding?
Drugs Made In America Acquisition reported a weighted average of 20.1 million basic shares outstanding in 2026 Q2.
What is Drugs Made In America Acquisition's market cap?
Based on its latest closing price, Drugs Made In America Acquisition (DMAA) has a market capitalization of about $218.2M.
When does Drugs Made In America Acquisition's fiscal year end?
Drugs Made In America Acquisition's fiscal year end, as registered with the SEC, is December 31.
Where is Drugs Made In America Acquisition headquartered?
Drugs Made In America Acquisition lists its business address in New York, New York in its SEC filings.